Industry to offer optional risk mitigation CE for pain relievers to practitionersFebruary 15, 2013
Health care practitioners in March will begin receiving offers of free, industry-sponsored continuing education (CE), as part of the U.S. Food and Drug Administration’s (FDA) new Risk Evaluation and Mitigation Strategy (REMS). This is designed to ensure the benefits of extended-release (ER) and long-acting (LA) opioids, such as Vicodin, Percodin, and Percoset, outweigh any risks.
Although drug makers are mandated to provide the education, health care practitioners will not be required to attend.
For additional information, visit www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM277916.pdf.